COVID-19: India finds 2 medicines against the Coronavirus.
Over 4 lakh people infected more than 13,000 deaths so far as India's COVID situation. The 'peak' of the pandemic yet. However, there is some good news India has cleared at the latest 2 medicines for production and sale. Glenmark pharmaceutical's FabiFlu and, hetero COVIFOR.How can these medicines b
FabiFlu and COVIFOR medicines.
Over 4 lakh people infected more than 13,000 deaths so far as India's COVID situation. The "peak" of the pandemic yet. However, there is some good news India has cleared at the latest 2 medicines for production and sale. Glenmark pharmaceutical's FabiFlu and, hetero COVIFOR.
How can these medicines be accessed and used?
- COVIFOR manufactured by India-based pharma hetero.
- It is a branded version of antiviral drug remdesivir.
- Used for treatment suspected or confirmed infections.
- It can be administered to children and adults with severe symptoms.
- Need to be administered intravenously in the hospital facility.
- In June, GOVT allowed Remdesivir to restricted emergency use.
Important features and information about FabiFlu.
- The medicine produced an 88% improvement in clinical trials.
- the drug will be available across the country with a prescription.
- Pack of 34 tablets costs Rs.3500.
- Each tablet costs Rs. 103.
- Suitable for the age group between 18-75. Production started, rolling out the drug next week.
- Earlier used in Russia, Japan, and China.
- Not recommended: people with kidney and liver ailments. It can be used on patients with coronavirus.
Important features and information about FabiFlu.
- The medicine produced an 88% improvement in clinical trials.
- the drug will be available across the country with a prescription.
- Pack of 34 tablets costs Rs.3500.
- Each tablet costs Rs. 103.
- Suitable for the age group between 18-75. Production started, rolling out the drug next week.
- Earlier used in Russia, Japan, and China.
- Not recommended: people with kidney and liver ailments. It can be used on patients with coronavirus.
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of 25hrNews and 25hrNews does not assume any responsibility or liability for the same.
(+91) 8081113111
pr@25hrnews.com
